The outcome in myasthenia gravis patients – an eight-year follow-up after finishing immunoabsorption therapy

Eight years ago four patients suffering from myasthenia gravis (MG) type C and E according to Compston with failed drug therapy were treated three times (one patient 11 times) by protein A immunoabsorption (Immunosorba ®, Excorim, Fresenius Hemocare GmbH, StWendel, Germany). No further immunoabsorpt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transfusion and apheresis science 2001-02, Vol.24 (1), p.95-98
Hauptverfasser: Schneidewind, J.M, Zettl, U.K, Winkler, R.E, Ramlow, W, Tiess, M, Michelsen, A, Hebestreit, G, Prophet, H, Pätow, W, Benecke, R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Eight years ago four patients suffering from myasthenia gravis (MG) type C and E according to Compston with failed drug therapy were treated three times (one patient 11 times) by protein A immunoabsorption (Immunosorba ®, Excorim, Fresenius Hemocare GmbH, StWendel, Germany). No further immunoabsorption treatments have been carried out. In addition, three patients were given a thymectomy. The present status of the patients was checked six and eight years thereafter. We could see a beneficial effect in all MG patients. The patients are fit for work; all have an improved Besinger index. The patients were used as their own controls. A higher anti-AChR-ab level six years after protein A immunoabsorption than at the beginning was seen in all patients combined with a less serious MG. In addition, their immunomodulation could be induced as seen in lymphocyte and inflammatory protein changes during the first 36 days after beginning immunoabsorption treatment. A larger population has to be investigated to verify these results.
ISSN:1473-0502
1878-1683
DOI:10.1016/S0955-3886(00)00125-9